Global Influenza Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

List of Tables

The global demand for Influenza Vaccine Market is presumed to reach the market size of nearly USD 26.751 BN by 2030 from USD 10.5 BN in 2022 with a CAGR of 10.95% under the study period 2023-2030.

Influenza vaccine, or flu shot, is a vaccine that protects against influenza, a highly contagious respiratory illness caused by influenza viruses. The vaccine works by prompting the body's immune system to release antibodies that can recognize and fight off the influenza virus. The influenza vaccine is typically given once a year, usually in the fall or winter, before the flu season begins. The vaccine is usually recommended for everyone over the age of six months, particularly individuals at higher risk of developing severe complications from influenza, such as the elderly, individuals with underlying medical conditions, and pregnant women.

Market Dynamics:

The high prevalence of influenza is one of the primary drivers of the influenza vaccine market. Influenza is a highly contagious respiratory illness that can lead to severe complications, particularly in high-risk populations (elderly and individuals with underlying medical conditions). Governments around the world have launched initiatives to scale up vaccination rates and reduce the burden of influenza on healthcare systems. These initiatives have led to increased awareness about the benefits of the influenza vaccine and increased demand for the vaccine. Advances in vaccine technology have made it easier to produce and distribute the influenza vaccine. Newer vaccine technologies, such as recombinant DNA and cell-based vaccines, offer several advantages over traditional egg-based vaccines, such as faster production times and improved efficacy. Increasing healthcare spending in developed and developing countries is driving the growth of the influenza vaccine market. Governments and private healthcare providers are investing in preventative measures such as vaccination to reduce the overall burden on healthcare systems. The growing elderly population is a key driver of the influenza vaccine market, as elderly individuals are at higher risk of developing severe complications from influenza.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of influenza vaccine. The growth and trends of influenza vaccine industry provide a holistic approach to this study.

Market Segmentation:

This section of the influenza vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Vaccine Type

Inactivated
Live Attenuated

By Indication

Quadrivalent
Trivalent

By Age Group

Pediatric
Adult

By Route Of Administration

Injection
Nasal Spray

By Distribution Channel

Hospitals & Pharmacies
Government & Institutional Supply
Other

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Influenza Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the influenza vaccine market include GSK plc, AstraZeneca, SINOVAC, Pfizer Inc, Vaxess Technologies Inc, CSL Limited, EMERGENT, Merck & Co., Inc., Viatris Inc., OSIVAX, EMERGEX VACCINES. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Product Code: VMR112110532

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . INFLUENZA VACCINE - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Vaccine Type
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Age Group
- 3.7.4 Market Attractiveness Analysis By Route Of Administration
- 3.7.5 Market Attractiveness Analysis By Distribution Channel
- 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY VACCINE TYPE

6.1 Overview by Vaccine Type
6.2 Historical and Forecast Data
6.3 Analysis by Vaccine Type
6.4 Inactivated Historic and Forecast Sales by Regions
6.5 Live Attenuated Historic and Forecast Sales by Regions

7 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 Quadrivalent Historic and Forecast Sales by Regions
7.5 Trivalent Historic and Forecast Sales by Regions

8 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY AGE GROUP

8.1 Overview by Age Group
8.2 Historical and Forecast Data
8.3 Analysis by Age Group
8.4 Pediatric Historic and Forecast Sales by Regions
8.5 Adult Historic and Forecast Sales by Regions

9 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

9.1 Overview by Route Of Administration
9.2 Historical and Forecast Data
9.3 Analysis by Route Of Administration
9.4 Injection Historic and Forecast Sales by Regions
9.5 Nasal Spray Historic and Forecast Sales by Regions

10 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY DISTRIBUTION CHANNEL

10.1 Overview by Distribution Channel
10.2 Historical and Forecast Data
10.3 Analysis by Distribution Channel
10.4 Hospitals & Pharmacies Historic and Forecast Sales by Regions
10.5 Government & Institutional Supply Historic and Forecast Sales by Regions
10.6 Other Historic and Forecast Sales by Regions

11 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY GEOGRAPHY

11.1. Top Company Share Analysis
11.2. Introduction
11.3. North America Sales Analysis
- 11.3.1. Overview, Historic and Forecast Sales Analysis
- 11.3.2. North America By Segment Sales Analysis
- 11.3.3. North America By Country Sales Analysis
- 11.3.4. United State Sales Analysis
- 11.3.5. Canada Sales Analysis
- 11.3.6. Mexico Sales Analysis
11.4. Europe Sales Analysis
- 11.4.1. Overview, Historic and Forecast Sales Analysis
- 11.4.2. Europe by Segment Sales Analysis
- 11.4.3. Europe by Country Sales Analysis
- 11.4.4. United Kingdom Sales Analysis
- 11.4.5. France Sales Analysis
- 11.4.6. Germany Sales Analysis
- 11.4.7. Italy Sales Analysis
- 11.4.8. Russia Sales Analysis
- 11.4.9. Rest Of Europe Sales Analysis
11.5. Asia Pacific Sales Analysis
- 11.5.1. Overview, Historic and Forecast Sales Analysis
- 11.5.2. Asia Pacific by Segment Sales Analysis
- 11.5.3. Asia Pacific by Country Sales Analysis
- 11.5.4. China Sales Analysis
- 11.5.5. India Sales Analysis
- 11.5.6. Japan Sales Analysis
- 11.5.7. South Korea Sales Analysis
- 11.5.8. Australia Sales Analysis
- 11.5.9. Rest Of Asia Pacific Sales Analysis
11.6. Latin America Sales Analysis
- 11.6.1. Overview, Historic and Forecast Sales Analysis
- 11.6.2. Latin America by Segment Sales Analysis
- 11.6.3. Latin America by Country Sales Analysis
- 11.6.4. Brazil Sales Analysis
- 11.6.5. Argentina Sales Analysis
- 11.6.6. Peru Sales Analysis
- 11.6.7. Chile Sales Analysis
- 11.6.8. Rest of Latin America Sales Analysis
11.7. Middle East & Africa Sales Analysis
- 11.7.1. Overview, Historic and Forecast Sales Analysis
- 11.7.2. Middle East & Africa by Segment Sales Analysis
- 11.7.3. Middle East & Africa by Country Sales Analysis
- 11.7.4. Saudi Arabia Sales Analysis
- 11.7.5. UAE Sales Analysis
- 11.7.6. Israel Sales Analysis
- 11.7.7. South Africa Sales Analysis
- 11.7.8. Rest Of Middle East And Africa Sales Analysis

12 . COMPETITIVE LANDSCAPE OF THE INFLUENZA VACCINE COMPANIES

12.1. Influenza Vaccine Market Competition
12.2. Partnership/Collaboration/Agreement
12.3. Merger And Acquisitions
12.4. New Product Launch
12.5. Other Developments

13 . COMPANY PROFILES OF INFLUENZA VACCINE INDUSTRY

13.1. Company Share Analysis
13.2. Market Concentration Rate
13.3. GSK plc
- 13.3.1. Company Overview
- 13.3.2. Company Revenue
- 13.3.3. Products
- 13.3.4. Recent Developments
13.4. AstraZeneca
- 13.4.1. Company Overview
- 13.4.2. Company Revenue
- 13.4.3. Products
- 13.4.4. Recent Developments
13.5. SINOVAC
- 13.5.1. Company Overview
- 13.5.2. Company Revenue
- 13.5.3. Products
- 13.5.4. Recent Developments
13.6. Pfizer Inc
- 13.6.1. Company Overview
- 13.6.2. Company Revenue
- 13.6.3. Products
- 13.6.4. Recent Developments
13.7. Vaxess Technologies Inc
- 13.7.1. Company Overview
- 13.7.2. Company Revenue
- 13.7.3. Products
- 13.7.4. Recent Developments
13.8. CSL Limited
- 13.8.1. Company Overview
- 13.8.2. Company Revenue
- 13.8.3. Products
- 13.8.4. Recent Developments
13.9. EMERGENT
- 13.9.1. Company Overview
- 13.9.2. Company Revenue
- 13.9.3. Products
- 13.9.4. Recent Developments
13.10. Merck & Co. Inc.
- 13.10.1. Company Overview
- 13.10.2. Company Revenue
- 13.10.3. Products
- 13.10.4. Recent Developments
13.11. Viatris Inc.
- 13.11.1. Company Overview
- 13.11.2. Company Revenue
- 13.11.3. Products
- 13.11.4. Recent Developments
13.12. OSIVAX
- 13.12.1. Company Overview
- 13.12.2. Company Revenue
- 13.12.3. Products
- 13.12.4. Recent Developments
13.13. EMERGEX VACCINES
- 13.13.1. Company Overview
- 13.13.2. Company Revenue
- 13.13.3. Products
- 13.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies